At the 101st American Association for Cancer Research (AACR) Annual Meeting in Washington, DC, in April, Pfizer presented a broad overview of its current oncology pipeline.
May 2010
Tyrosine Kinase Inhibitors (TKIs) are indicated for the treatment of a variety of malignancies, due to their ability to interfere with cell communication and growth. This review focuses on interactions that affect TKI metabolism.
Advertisement
Advertisement
Trending on HCPLive
1
CT Air Trapping Metric May Predict Post-BLVR Pneumothorax Risk
2
Mifepristone Improves HbA1c, Weight in Poorly Controlled T2D, Regardless of GLP-1 Treatment
3
Saroglitazar Targets Bile Acid Dysregulation, Inflammation in PBC, With Raj Vuppalanchi, MD
4
MAESTRO-NASH: Resmetirom May Reduce Cardiovascular Risk in MASH, With or Without Statins
5